Takeda Copes With FDA Delays, Yen Appreciation and Acquisition Drags in 2008

TOKYO - U.S. FDA has moved back its PDUFA date on yet another Takeda drug - this time dipeptidyl peptidase-4 inhibitor SYR-322 (alogliptin) - making it the third Takeda drug facing FDA delays this year, Takeda President Yasuchika Hasegawa told a Nov. 4 earnings conference